The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA
Atlethe's Foot
January 21, 2015 – On this day, the U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an …